| Today’s Big NewsJun 6, 2025 |
| By Darren Incorvaia At a June 5 cell and gene therapy roundtable hosted by the FDA, Department of Health and Human Services Secretary Robert F. Kennedy Jr. asked the assembled scientists and advocates to provide a list of regulations they’d like to see gone. |
|
|
|
By Gabrielle Masson As favor in the general market swings away from cell therapy, Immatics’ CEO is choosing to focus on what he can control: raising the bar for his biotech’s investigational treatment. |
By James Waldron Otsuka Pharmaceutical has shared data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio levels. |
Sponsored by Thermo Fisher Scientific Austin Read of Thermo Fisher Scientific discusses how combining biospecimens with real-world data is advancing diagnostics, treatment and the future of patient care. |
|
From gene therapy pipelines to early-stage VC deals, biotech leaders are seeking clarity in the chaos. That’s why companies are sharing their insights through Fierce content hubs — with weekly features right here in your inbox. See how others are shaping the narrative.
|
|
By Nick Paul Taylor TegMine Therapeutics has secured certain rights to OBI Pharma’s antibody-drug conjugate technology, advancing the efforts of former Stemcentrx scientists to treat cancer by targeting carbohydrates. |
Sponsored by Bayer Discover how Bayer and BlueRock are redefining biotech partnerships. From breakthrough Parkinson’s therapies to a unique “arm’s-length” model, this episode of The Top Line dives into what makes their collaboration a blueprint for the future. |
By Darren Incorvaia,Zoey Becker Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, who brings to the table two decades of industry experience. Before his most recent position as Rafael Holdings’ CEO, Conkling spent over 10 years at Novartis including as commercial lead for the launch of the first ever approved CAR-T therapy, Kymriah, in 2017. |
Sponsored by Marken, UPS Healthcare Precision Logistics Radiopharma is revolutionizing modern medicine. Discover how precision logistics empowers faster, safer delivery of life-impacting therapies when every second counts. |
By Conor Hale The companies that make up this class of the Fierce 15 exemplify the idea of moving the field forward by using innovation to build upon what’s come before. |
By Nick Paul Taylor Orca Bio is preparing to make a splash in the cell therapy market. The biotech has hired Steve Gavel as chief commercial officer, securing itself a leader with cell therapy expertise accrued at Legend Biotech and Celgene. |
By Angus Liu The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. AstraZeneca and Daiichi Sankyo trotted out Enhertu's detailed data in first-line breast cancer. Regeneron signed on a GLP-1/GIP candidate from Hansoh Pharma. And more. |
By Noah Tong,Paige Minemyer As senators seek a path forward for President Trump's "big beautiful bill," Medicare cuts are reportedly on the table, according to media reports. The version of the bill that passed the House in May includes work requirements imposed sooner and changes to state-directed payments, cost-sharing reductions, eligibility checks and gender-affirming care. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we’re examining the future of tech-enabled home care and the policy decisions that could determine whether these models become permanent fixtures in the U.S. healthcare system. |
|
|---|
|
|
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
